CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has initiated a Phase I clinical trial of its INTERCEPT Blood System for red blood cells. Developed to improve the safety of red blood cell transfusions, the system is designed to inactivate pathogens that may be present in donated red blood cells, while preserving the blood products’ therapeutic properties. An estimated 34 million units of red blood cells are transfused worldwide each year to support patients with anemia due to trauma or a wide range of blood disorders.
